^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT3216

    i
    Other names: BNT3216, PM1032, BNT-3216
    Associations
    News

    Trials

    Company:
    BioNTech
    Drug class:
    CLDN18.2 inhibitor, CD137 agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors (NCT05839106)
    Phase 1/2
    Biotheus Inc.
    Recruiting
    Last update posted :
    05/05/2023
    Initiation :
    07/08/2022
    Primary completion :
    04/10/2025
    Completion :
    12/31/2025
    CLDN18
    |
    CLDN18.2 positive
    |
    BNT3216